|
Targeting KRAS Mutations in Pancreatic Cancer:
Insights from Mouse Models and Clinical Prospects |
 |
Wednesday, May 28, 2025 |
 |
10:00 EDT / 15:00 BST / 16:00 CEST |
|
|
 |
| Mariano Barbacid, PhD |
| • |
Group Leader of Experimental Oncology Group,
Molecular Oncology Program |
|
| • |
Spanish National Cancer Research Centre (CNIO),
Madrid, Spain |
|
| • |
Pioneer in Cancer Research and Discoverer of the First
Human Oncogene – HRAS |
|
|
| In This Webinar, You Will Learn: |
| • |
The Progress and Limitations of KRAS Inhibitors |
| • |
Alternative Strategy: Targeting Multiple KRAS Signaling Nodes |
| • |
Future Directions: Translating Preclinical Data to Clinical
Applications |
|
A recording of the webinar will be shared to all registrants.
Participants can request a webinar certificate by contacting
Marketing@medchemexpress.com |
| About This Webinar: |
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to
late diagnosis and limited treatments, primarily relying on old
cytotoxic drugs. Despite advances in understanding PDAC
biology—driven by KRAS mutations and tumor suppressor loss—KRAS
inhibitors like Sotorasib have shown limited efficacy, with rapid
resistance. Instead of targeting KRAS directly, a novel approach
combines inhibition of downstream (RAF1), upstream (EGFR), and
orthogonal (STAT3) signaling nodes. In mouse models, this
triple-targeting strategy induced durable tumor regression without
significant toxicity. Pharmacological validation is underway,
offering potential for improved PDAC therapies. |
|
|
| MCE Webinar |
The MCE webinar is committed to offering an official platform for
global experts and researchers in the fields of medicine, pharmacy,
biology, and chemistry.
By facilitating knowledge exchange, the MCE webinar aims to
contribute to the global biopharmaceutical industry by promoting
extensive sharing of information and expertise. |
|
|
|
|
|
|
|
|
Products are for research use only and are not intended for human use. We do
not sell to patients.
|
|
|
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
